Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
We welcome Patrik Norgren as Interim Chief Financial Officer
Patrik comes to Cinclus Pharma with more than 20 years of experience working as interim CFO at several Swedish companies. Welcome, Patrik!
Watch the Virtual KOL Event on healing the unhealed
Now you can watch Cinclus Pharma’s virtual KOL event from December 11, 2025 featuring Professor Prateek Sharma, MD, who joins company management to discuss the unmet need and current treatment landscape for GERD.
CEO Christer Alhberg presents at Redeye Life Science Day 2025
Watch the full presentation by CEO Christer Ahlberg about Cinclus Pharma and the development of linaprazan glurate, presented at Redeye Life Science Day December 3.
Cinclus Pharma invites to KOL event
Cinclus Pharma Holding AB (publ) will host a virtual event featuring Professor Prateek Sharma from the Cancer Center in Kansas City, to provide deeper insights on the current treatment landscape and the unmet medical need among patients with erosive…
Cinclus Pharma in media
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
2024-09-23Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
